Growth differentiation factor-15 and white matter hyperintensities in cognitive impairment and dementia. Issue 33 (August 2016)

• Record Type: Journal Article
• Authors: Chai, Yuek Ling; Hilal, Saima; Chong, Jenny P.C.; Ng, Yan Xia; Liew, Oi Wah; Xu, Xin; Ikram, Mohammad Kamran; Venketasubramanian, Narayanaswamy; Richards, A. Mark; Lai, Mitchell K.P.; Chen, Christopher P.
• Other Names: Tusconi. Massimo section editor.
• Is Part Of: Medicine. Volume 95:Issue 33(2016)
• Publication Date: 2016-08
• Subjects: biomarker -- cerebrovascular disease -- cognitive impairment -- dementia -- growth differentiation factor-15 -- white matter hyperintensities; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000004566
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Vascular pathology plays an important role in the development of cognitive decline and dementia. In this context, growth differentiation factor-15 (GDF-15) has been suggested to be a biomarker due to its regulatory roles in inflammatory and trophic responses during tissue injury. However, limited data exist on the associations of GDF-15 with either cerebrovascular disease (CeVD) burden or the spectrum of cognitive impairment. Therefore, we aimed to study peripheral levels of GDF-15 incognitive impairment no dementia (CIND) or Alzheimer disease (AD) subjects assessed for CeVD using a case–control cohort design, with cases recruited from memory clinics and controls from memory clinics and the community. All subjects underwent detailed neuropsychological assessment, 3-Tesla magnetic resonance imaging, and venous blood draw. Subjects were classified as CIND or AD based on clinical criteria, while significant CeVD was defined as the presence of cortical infarcts and/or 2 lacunes or more, and/or confluent white matter hyperintensities (WMHs) in 2 or more brain regions. A total of 324 subjects were included in the study, of whom 80 had no cognitive impairment, 144 CIND and 100with AD. Higher GDF-15 levels were significantly associated with disease groups, especially in the presence of CeVD, namely, CIND with CeVD (odds ratios [OR]: 7.21; 95% confidence interval [CI]: 2.14–24.27) and AD with CeVD (OR: 21.87; 95% CI: 2.01–237.43). Among the different CeVD markers, only WMH was associated with higher GDF-15 levels (OR: 3.97; 95% CI: 1.79–8.83). The associations between GDF-15 and cognitive impairment as well as with WMH remained significant after excluding subjects with cardiovascular diseases. In conclusion, we showed that increased GDF-15 may be a biomarker for CIND and AD in subjects with WMH. Abstract : Supplemental Digital Content is available in the text